← Back to Search

MyProstateScore 2.0 for Prostate Cancer

N/A

Waitlist Available

Research Sponsored by Qure Healthcare, LLC

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up [9 months]

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing the MPS 2.0 Test, a new tool for early prostate cancer detection. It involves physicians and their patients to collect real-world data. The test identifies markers indicating prostate cancer, aiding in early diagnosis.

Eligible Conditions

Prostate Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ [9 months]

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~[9 months]

This trial's timeline: 3 weeks for screening, Varies for treatment, and [9 months] for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Baseline levels of variation in the assessment, surveillance, and management of patients at high risk for prostate cancer among all study participants.

Differences between expected quality of care and actual quality of care

Differences in evidence-based decision making

+3 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: MyProstateScore 2.0Experimental Treatment1 Intervention

The intervention will receive information regarding the MyProstateScore 2.0 test and will be given the test results in their round of CPV information and for each sample that they submit.

Group II: Control arm - Baseline comparisonActive Control1 Intervention

The Control group treats their simulated patients using standard practice and has no introduction to the new MyProststate 2.0 test.

Do I qualify?Apply below to find out